Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Bonus plan approved
Inv. presentation
Acq. announced
Director departure
CUBIST PHARMACEUTICALS INC (CBST) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2011 BW Cubist Pharmaceuticals and the New England Patriots Radio Network Continue Program to Recognize Innovative Science Teachers
07/14/2011 BW Cubist Pharmaceuticals 2Q11 Total Net Revenues $176.8 Million
06/27/2011 BW Cubist Pharmaceuticals Appoints Charles Laranjeira as Senior Vice President, Technical Operations
05/31/2011 BW Cubist Pharmaceuticals to Present at June 2011 Investor Conferences
05/03/2011 BW Cubist Pharmaceuticals to Present at May Investor Conference
05/02/2011 BW Cubist Pharmaceuticals' Antibiotic Programs Featured in 18 Abstracts at 21st ECCMID/27th ICC Joint Congress
04/14/2011 BW Cubist Pharmaceuticals 1Q11 Total Net Revenues Up 13% to $162.5 Million; 1Q11 U.S. Net Revenues for CUBICIN Up 14% to $153.7 Million
03/07/2011 BW Cubist Pharmaceuticals Board of Directors Names Kenneth Bate Non-Executive Chair of the Board
03/01/2011 BW Cubist Pharmaceuticals to Present at March Investor Conference
12/14/2010 BW Cubist Pharmaceuticals Revises 2010 Net Revenue Guidance
12/08/2010 BW Cubist Pharmaceuticals to Present at December Investor Conference
12/01/2010 BW Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
11/08/2010 BW The Boston Globe Names Cubist to Top Places to Work 2010
10/26/2010 BW Cubist Pharmaceuticals to Present at November Investor Conferences
10/19/2010 BW Cubist Prices $400 Million of Convertible Senior Notes
10/19/2010 BW Cubist Prices $400 Million of Convertible Senior Notes
10/18/2010 BW Cubist Announces Offering of Convertible Senior Notes
10/14/2010 BW Cubist Pharmaceuticals 3Q10 Total Net Revenues Up 13% to $162.1 Million
09/13/2010 BW Cubist Pharmaceuticals to Host Product Pipeline Investor and Analyst Event
09/10/2010 BW Cubist Pharmaceuticals' Antibiotic Programs Featured in 47 Presentations at 50th ICAAC
09/08/2010 BW Cubist Pharmaceuticals Prepares for Continued Growth
09/08/2010 BW Cubist Pharmaceuticals to Present at September Investor Conferences
08/20/2010 BW Cubist Pharmaceuticals Named One of Fortune's “100 Fastest-Growing Companies???
08/10/2010 BW Cubist Pharmaceuticals and the New England Patriots Radio Network Renew Program to Recognize Innovative Science Teachers
07/19/2010 BW Cubist Pharmaceuticals to Ring the NASDAQ Stock Market Opening Bell
07/15/2010 BW Cubist Pharmaceuticals 2Q10 Total Net Revenues Up 29% to $168.5 Million
07/13/2010 BW Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections
06/30/2010 BW Cubist Pharmaceuticals Enrolls First Patient in CXA-201 Phase 2 Study in Complicated Intra-Abdominal Infections
06/29/2010 BW Cubist Announces All Objectives Met in Phase 2 CXA-101 Complicated Urinary Tract Infections Study
06/11/2010 BW Cubist Pharmaceuticals to Oppose Teva's Attempt to Add Inequitable Conduct Defense in Patent Infringement Action
05/12/2010 BW Markman Hearing in CUBICIN® Patent Litigation Rescheduled to June 9, 2010
04/30/2010 BW Cubist Pharmaceuticals to Present at May 2010 Investor Conferences
04/15/2010 BW Cubist Pharmaceuticals 1Q10 Total Net Revenues Up 19% to $144.1 Million
04/08/2010 BW Cubist Pharmaceuticals Enrolls 1st Subject in Phase 2 Trial for Therapy to Treat Clostridium Difficile-Associated Diarrhea, or CDAD
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy